1 Racine-Poon L, Botta T, Chang W.Efficacy, pharmacodynam-ics, and pharmacokinetics of CGP51901, on anti -immunglobulin E Chimeric monoclonal antibody, in patientswith seasonal aller-gic rhinitis[J]. Clin Pharmacol Ther, 1997;62:675-90
2 Hochaus G, Schmidt EW, Rominger KL.Pharmacokinetic/ dy-namic correlation of pulmonary and cardiac effect of fenoterol in asthmatic patients after different routes of administration[J]. Pharm Res, 1992;9:291-7
3 Dingemanse J, Häusler J, Gering W, Ihmsen H, Albrecht S. Pharmacokinetic-pharmacodynamic modeling of the EEG effects of RO 48-6791, a new short -acting benzodiazepine, in young and elder subjects[J]. Br J Anaesth, 1997;79:567-74
4 Sun YN, DuBois DC, Almon RR.Dose-dependence and re-peated-dose studies for receptor/ gene-mediated pharmacody-namic of methylprednisolone on glucorticoid recptor down-regu-lation and tyrosine aminotransferase induction in rat liver[J]. J Pharmacokinet Biopherm, 1998;26:619-48
5 Derendorf H, HochhausG, MullmannH.Receptor -based phar-macokinetic-pharmacodynamic analysis of corticosteroids[J]. J Clin Pharmacol, 1993;33:115-23
6 Hartmut D, BerndM.Modeling of pharmacokinetic/ pharmcody-namic(PK/PD)Relationships:Concepts and perspectives[J]. Pharm Res, 1999;16:176-85
7 Johan L, Gabrielsson, Daniel L, Weiner.Methodology for phar-macokinetic/pharmacodynemic data analysis[J]. PSTT, 1999; 2:244-52
8 Sun YN, McKay LI, Dubois DC.Pharmacokinetic/ pharmaco-dynamic model for corticosteroid receptor /gene-mediated mech-anism[J]. J Pharmacol Exp Ther, 1999;288:720-8
9 Valle M, Garrido MJ, Pavon JM.Pharmacokinetic-pharmcody-namic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-o-desmethyltramadol and (-)-o-desmethyltramadol.In rats[J]. J Pharmacol Exp Ther, 2000; 293:646-53
10 Marchand S, Pariat C, Bouquet S.Pharmacokinetic-pharmaco-dynamic modeling of the convulant interaction between mor-floxacin and biphenyl acetic acid in rats[J]. Br J Pharmacol, 2000;8:1609-16
11 Cheikh D, Frederic Y, Bois.Pharmacokinetic-pharmacodynam-ic models for categorical[J]. Pharmacol Toxical, 2005;41:55-65
12 Rosseau A, Marquet P.Adaptive control methods for the dose individualization of anticancer agents[J]. Chin Pharmacokinet, 2000;38:315-53
13 NielsFricmodt-Moller.How predictive is PK/ PD for antibacte-rial agents[J]. Int J Anlimicrob Agents, 2002;19:333-9
14 Shliner LB, Steimer JL.Pharmacokinetic/pharmacodynamic modeling in drug development[J]. Annu Rev pharmacol Toxi-col, 2000;40:67-95
15 ColburnWA, Lee JW, Biomarkers.Validation and pharmacoki-netic-pharmcodynamic modeling[J]. Clin pharmcokinet, 2003; 42:997-1022
16 Theil FP, Guentert TW, Haddads, Poulin P.Utility of physio-logically basedpharmacokinetic models to drug development and rational drug discovery candadate selection[J]. Toxicol Lett, 2003;138:29-49
17 Mager DE, Jusko WJ.Quantitative structure-pharmacokinetic/ pharmacodynamic relationships of corticosteroids in man[J]. J Pharm Sci, 2002;91:2441-51
18 Hideyoshi H, Shinya I, Yumiko U, Mari T, Hiroshi K.Opti-mization of antitumor effect of liposomally excapsulated doxoru-bicin based on simulations by pharmacokinetic/ pharmacodynam-ic modeling[J]. J Controlled Release, 1999;61:93-106 |
